EUCTR2010-023611-34-NL
Active, not recruiting
Not Applicable
A Phase II Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects with Acute Coronary Syndrome - CHI SQUARE
Cerenis Therapeutics0 sites500 target enrollmentMay 3, 2011
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Symptoms of Acute Coronary Syndrome
- Sponsor
- Cerenis Therapeutics
- Enrollment
- 500
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female under 75 years of age, acute chest pain and diagnosis of ST segment elevation or non\-ST elevation myocardial infarction or unstable angina, clinically indicated coronary angiography, evidence of coronary artery disease, and an appropriate target coronary artery.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Subjects weighing more than 120 kg, uncontrolled diabetes, triglycerides greater than 500 mg/dl, baseline IVUS of unacceptable quality, subjects for whom CABG is planned, hemodynamically or clinically unstable, and ejection fraction less than 35%.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Global Prevention of Asthma in Children StudyACTRN12607000633482ational Institute of Allergy and Infectious Diseases200
Active, not recruiting
Not Applicable
A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment with SA4503, 1 mg or 3 mg Once Daily for 8 Weeks, in Subjects With Major Depressive DisorderMajor Depressive Disorder (MDD)MedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2007-002740-16-FIM's Science Corporation150
Active, not recruiting
Phase 1
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's SyndromeEUCTR2016-000101-37-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO120
Active, not recruiting
Phase 1
A randomized, blinded clinical study comparing the combination durvalumab and olaparib to durvalumab alone for patients with advanced bladder cancernresectable Stage IV Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10022880Term: Invasive bladder cancer stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-004556-27-ESAstraZeneca AB154
Active, not recruiting
Phase 1
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's Syndromesubjects with moderate to severe Sjögren's syndromeMedDRA version: 19.1Level: LLTClassification code 10040766Term: Sjogren's diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10042846Term: Syndrome Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10040765Term: Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10048676Term: Sjogren-Larsson syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2016-000101-37-GRBristol-Myers Squibb International Corporation160